Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
about
The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.EGFR-TKIs resistance via EGFR-independent signaling pathways.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells.Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
P2860
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase 1/2 study of rilotumumab ...... ed non-small cell lung cancer.
@en
Phase 1/2 study of rilotumumab ...... ed non-small cell lung cancer.
@nl
type
label
Phase 1/2 study of rilotumumab ...... ed non-small cell lung cancer.
@en
Phase 1/2 study of rilotumumab ...... ed non-small cell lung cancer.
@nl
prefLabel
Phase 1/2 study of rilotumumab ...... ed non-small cell lung cancer.
@en
Phase 1/2 study of rilotumumab ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
Phase 1/2 study of rilotumumab ...... ced non-small cell lung cancer
@en
P2093
Ahmad A Tarhini
Autumn Gaither-Davis
Daniel P Petro
David M Friedland
Imran Rafique
Jill M Siegfried
Jose Gomez-Garcia
Laura P Stabile
Liza C Villaruz
Mark A Socinski
P2860
P304
P356
10.1002/CNCR.30717
P407
P577
2017-05-04T00:00:00Z